A partner monoclonal antibody to Moab 730 kills 100% of DU145 and PC3 androgen-independent cancer cells

Journal of biosciences

G P Talwar1¹  Rahul Pal³  Hemant Kumar Vyas¹  Nirmal K Lohiya² 

[1] Talwar Research Foundation, E-8, Neb Valley, New Delhi 110 068, India$$;Center for Advanced Studies, Department of Zoology, University of Rajasthan, Jaipur 302 055, India$$;Immuno-endocrionology Lab, National Institute of Immunology, New Delhi 110 067, India$$

关键词: Antibody binding by FACS;    complement-mediated lysis;    cytotoxicity;    differing epitopes;    MTT;   

DOI  :  

来源: Indian Academy of Sciences

【 摘 要 】

A number of therapeutic options are available for patients with prostate carcinoma till the time that the tumour is hormone dependent. However, no fully effective therapy is available for the treatment of androgen-independent prostate carcinomas. Antibodies directed at epitopes unique to or overexpressed on the cancer cells could be of therapeutic utility. A monoclonal antibody (Moab) 2C4 has been generated, which binds with cells of two androgenindependent prostate cancers, DU145 and PC3, and does not bind to peripheral blood leukocytes (PBLs) of healthy donors. This antibody, along with the previously developed Moab 730, kills 100% of both DU145 and PC3 cells in the presence of complement and does not have a deleterious effect on PBLs of healthy males. The anti-tumour action of the two antibodies prevents the establishment of DU145 cell tumour in nude mice in vivo. Moab 2C4 in combination with 730 has potential for use as therapy for androgen-independent cancers.

【 授权许可】

Unknown